Characterization of Angelman Syndrome
Learn more about:
Related Clinical Trial
Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype
Angelman Syndrome Video Assessment (ASVA) Source Material Study
The Global Angelman Syndrome Registry
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
Angelman Syndrome Natural History Study- FAST UK
A Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89zr] Labeled RO7248824 In Healthy Male Participants
Angelman Syndrome Natural History Study
A Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of RO7248824 In Participants With Angelman Syndrome
A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome
A Study in Adults and Adolescents With Angelman Syndrome
Angelman Syndrome (AS) Biomarker Study
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome
Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome
Characterization of Angelman Syndrome
Nutritional Formulation for Angelman Syndrome
Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome
A Trial of Levodopa in Angelman Syndrome
Minocycline in the Treatment of Angelman Syndrome
Angelman Syndrome Italian Registry